Naratriptan Inteli (Naratriptan Hydrochloride)

Naratriptan, the active ingredient in Naratriptan Inteli, is a selective serotonin 5‑HT1B/1D receptor agonist (triptan) presented as an oral tablet for oral use. It is indicated for the acute treatment of migraine attacks in adult patients.

GNH USA supplies Naratriptan Inteli as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product meets EU quality standards and is manufactured under strict Good Manufacturing Practice guidelines.

Naratriptan is used to treat migraine, a neurovascular headache disorder, by targeting the trigeminovascular pathway.

- Migraine attacks: provides rapid relief of headache pain and associated symptoms such as nausea and photophobia. - Migraine with aura: aborts attacks after the onset of visual or sensory aura. - Acute episodic migraine: reduces the need for additional rescue medication.

Common side effects are generally mild and transient, reflecting the drug's vascular and central nervous system activity.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Dizziness: sensation of light‑headedness or unsteadiness. - Fatigue: feeling unusually tired or weak. - Dry mouth: reduced salivation. - Tingling sensations: paresthesia in extremities. - Somnolence: mild sleepiness.

Serious or Rare Side Effects: - Chest pain or tightness: possible cardiac ischemia. - Severe hypertension: abrupt rise in blood pressure. - Serotonin syndrome: agitation, hyperthermia, muscle rigidity. - Allergic reaction: rash, itching, swelling, or anaphylaxis. - Ischemic cardiac events: myocardial infarction in susceptible patients.

Before prescribing Naratriptan, clinicians should evaluate patient‑specific risk factors and follow safe handling practices.

- Assess cardiovascular risk: review history of coronary artery disease, angina, or stroke. - Avoid use in uncontrolled hypertension: contraindicated when blood pressure is not well managed. - Do not combine with MAO inhibitors: risk of serotonin syndrome. - Caution in patients over 65 years: monitor for increased adverse effects. - Store at room temperature: keep in the original pack, protect from moisture and direct sunlight.

Naratriptan may interact with several drug classes; interactions are categorized by clinical significance.

Major Interactions (Avoid): - MAO inhibitors: concurrent use can precipitate serotonin syndrome. - Other triptans or ergot derivatives: additive vasoconstriction may increase cardiovascular risk. - SSRIs, SNRIs, or other serotonergic agents: heightened risk of serotonin syndrome.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: may enhance blood pressure‑lowering effects. - Oral contraceptives: possible reduction in contraceptive efficacy. - CYP1A2 inhibitors (e.g., fluvoxamine): may increase naratriptan plasma concentrations.